RxDoctor Payments DataLook up a doctor →

Pankaj Patel, MD

Gastroenterology · South Bend, INNPI 1124022082

Payments from drug & device makers

$2,268,677in general payments, 2019–2025

Across 1,186 payments — averaging $1912.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$929K
  • Genentech, Inc.$914K
  • Novo Nordisk AS$155K
  • Novartis$126K
  • Bausch Health US, LLC$84K
  • GSK$30K
  • plus $31K from 40 others
$1,849in research payments, 2019–2025

Across 2 payments — averaging $924.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

What the payments were for

  • Travel & lodging$8728%
  • Food & beverage$9,61491%
  • Education$170%
  • Entertainment$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,268,677 in reported general payments places this provider in the 95th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$134,107
Medicare patients
578
Services billed
963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase19$32,142
LinzessLinaclotide33$26,235
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates183$11,886
Esomeprazole Magnesium122$8,987
Dexlansoprazole DrDexlansoprazole35$8,378
Mesalamine12$4,556
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl313$4,035
Omeprazole252$3,819
SutabSod Sulf/Pot Chloride/Mag Sulf22$3,573
Mesalamine ErMesalamine24$3,307
Balsalazide Disodium14$2,806
Ursodiol31$2,110
Lubiprostone14$2,096
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl102$1,583
Pantoprazole Sodium108$1,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$928,626$58,37752 claims
Braintree Laboratories, Inc.Sutab$3,084$3,57322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →